chr19-6496032-C-A
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM2PP2PP3_ModeratePP5_Very_Strong
The ENST00000264071.7(TUBB4A):c.467G>T(p.Arg156Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R156C) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000264071.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TUBB4A | NM_006087.4 | c.467G>T | p.Arg156Leu | missense_variant | 4/4 | ENST00000264071.7 | NP_006078.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TUBB4A | ENST00000264071.7 | c.467G>T | p.Arg156Leu | missense_variant | 4/4 | 1 | NM_006087.4 | ENSP00000264071 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hypomyelinating leukodystrophy 6 Pathogenic:2Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2014 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 17, 2021 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Experimental studies have shown that this variant affects TUBB4A protein function (PMID: 28275661). This variant has been observed in individual(s) with TUBB4A-related conditions (PMID: 24742798, 26795593). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 135659). This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with leucine at codon 156 of the TUBB4A protein (p.Arg156Leu). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and leucine. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 29, 2014 | The c.467G>T (p.R156L) alteration is located in exon 4 (coding exon 4) of the TUBB4A gene. This alteration results from a G to T substitution at nucleotide position 467, causing the arginine (R) at amino acid position 156 to be replaced by a leucine (L). The alteration is not observed in healthy cohorts:_x000D_ Based on data from the NHLBI Exome Sequencing Project (ESP), the TUBB4A c.467G>T alteration was not observed among 6,503 individuals tested. Allele frequency data for this nucleotide position are not currently available from the 1000 Genomes Project and the alteration is not currently listed in the Database of Single Nucleotide Polymorphisms (dbSNP)._x000D_ Though some variants may appear to be rare due to database-specific ethnic underrepresentation, rare missense alleles commonly exhibit a deleterious effect on protein function (Kryukov, 2007; Tennessen, 2012). IF USED, PULL THESE INTO REFERENCES:_x000D_ Kryukov GV, et al. (2007) Am J Hum Genet 80:727-739. Tennessen JA, et al. (2012) Science 337(64):64-69. The amino acid change has been observed in affected individuals: _x000D_ This missense alteration was reported in de novo form in a 4-year old Caucasian girl tested at Ambry Genetics through exome sequencing with static hypomyelinating leukodystrophy (Purnell, 2014). Her features included hypotonia, global delay, truncal ataxia, nystagmus, esotropia, and hypomyelination on brain MRI with minor atrophy of the brain stem and cerebellum. The altered amino acid is conserved throughout evolution:_x000D_ The p.R156 amino acid is completely conserved in available vertebrate species. The amino acid is located in a functionally important protein domain:_x000D_ The p.R156L amino acid is located within the H4 a-helix of the globular N-terminal nucleotide binding domain of the tubulin b-4A protein (Lowe, 2001). The alteration is predicted deleterious by in silico models:_x000D_ The p.R156L alteration is predicted to be probably damaging by Polyphen and deleterious by SIFT in silico analyses. Based on the available evidence, this alteration is classified as pathogenic. - |
TUBB4A-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 20, 2024 | The TUBB4A c.467G>T variant is predicted to result in the amino acid substitution p.Arg156Leu. This variant has been reported as de novo in an individual with hypotonia, nystagmus, and hypomyelination (Purnell et al. 2014. PubMed ID: 24742798), de novo in an individual with unclassified epilepsy (Table S3, Helbig et al 2016. PubMed ID: 26795593), and with unknown inheritance in two individuals with hypomyelination (Table S1, Gavazzi et al. 2021. PubMed ID: 34514881). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at